The Next Generation of Prognosis: Novel Biomarkers in AML and MDS
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 31 October 2026 | Viewed by 15
Special Issue Editors
Interests: acute myeloid leukemia; myelodysplastic neoplasms
Interests: acute myeloid leukemia; myelodysplastic neoplasms
Special Issue Information
Dear Colleagues,
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are clinically and biologically heterogeneous hematologic malignancies in which traditional prognostic models based on cytogenetics and clinical parameters are often insufficient. The classical prognostic tools have been revitalized and updated thanks to modern technological and biological breakthroughs—primarily immunophenotype and genomic data, which are now routinely incorporated into modern classification systems. However, even with increasing data, identifying patients with a higher risk of relapse or drug resistance remains a challenge. In this light, a comprehensive understanding of genomic, epigenetic, biochemical, and immune biomarkers marks a shift toward personalized prognosis and treatment strategies in AML and MDS, paving the way for precision medicine.
We are pleased to invite you to publish your clinical and experimental research regarding novel biomarkers in AML and MDS in this Special Issue.
The aim of this Issue is to discuss the molecular mechanisms, clinical and potential therapeutic implications of novel biomarkers, and their implementation in everyday practice.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: biomarker biology in AML and MDS, novel biomarkers and their clinical utility, prognostic factors in AML and MDS, and the significance and advances of MRD in AML and MDS.
We look forward to receiving your contributions.
Dr. Marijana Virijevic
Prof. Dr. Andrija Bogdanovic
Dr. Ljubomir Jakovic
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute myeloid leukemia
- myelodysplastic syndrome
- biomarkers
- minimal residual disease
- novel prognostic factors
- immune-related biomarkers
- molecular targets
- genomics
- risk stratification
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
